Sionna Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 to develop novel treatments for cystic fibrosis by targeting NBD1, the site of the most common CF-causing mutation. The company is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators designed to work synergistically to normalize CFTR function beyond current approved therapies.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2024
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
